Eyad Elkord

List of Publications by Year in Descending Order

105 papers	5,724 citations	36 h-index	75 g-index
123 ext. papers	7,455 ext. citations	6.5 avg, IF	6.65 L-index

#	Paper	IF	Citations
105	Intrinsic and acquired cancer immunotherapy resistance **2022**, 463-497		
104	Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients.. *Frontiers in Immunology*, **2022**, 13, 870283	8.4	1
103	Role of T Regulatory Cells and Myeloid-Derived Suppressor Cells in COVID-19.. *Journal of Immunology Research*, **2022**, 2022, 5545319	4.5	0
102	Associations of Complete Blood Count Parameters with Disease-Free Survival in Right- and Left-Sided Colorectal Cancer Patients. *Journal of Personalized Medicine*, **2022**, 12, 816	3.6	1
101	Transcriptomic Profiling of Circulating HLA-DR Myeloid Cells, Compared with HLA-DR Myeloid Antigen-presenting Cells. *Immunological Investigations*, **2021**, 50, 952-963	2.9	1
100	Role of circular RNAs in colorectal tumor microenvironment. *Biomedicine and Pharmacotherapy*, **2021**, 137, 111351	7.5	3
99	Integrated whole transcriptome and small RNA analysis revealed multiple regulatory networks in colorectal cancer. *Scientific Reports*, **2021**, 11, 14456	4.9	1
98	Differential gene expression of tumor-infiltrating CD33 myeloid cells in advanced- versus early-stage colorectal cancer. *Cancer Immunology, Immunotherapy*, **2021**, 70, 803-815	7.4	2
97	T-cell responses and therapies against SARS-CoV-2 infection. *Immunology*, **2021**, 162, 30-43	7.8	60
96	Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment. *Cancer Immunology, Immunotherapy*, **2021**, 70, 2103-2121	7.4	5
95	Transcriptome of CD8 tumor-infiltrating T cells: a link between diabetes and colorectal cancer. *Cancer Immunology, Immunotherapy*, **2021**, 70, 2625-2638	7.4	0
94	SnoRNAs and miRNAs Networks Underlying COVID-19 Disease Severity. *Vaccines*, **2021**, 9,	5.3	5
93	Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors. *Vaccines*, **2021**, 9,	5.3	1
92	Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.. *Frontiers in Immunology*, **2021**, 12, 707159	8.4	2
91	RNA-Seq Analysis of Colorectal Tumor-Infiltrating Myeloid-Derived Suppressor Cell Subsets Revealed Gene Signatures of Poor Prognosis. *Frontiers in Oncology*, **2020**, 10, 604906	5.3	6
90	Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19. *Cells*, **2020**, 9,	7.9	65
89	DNA methylation in the promoters of PD-L1, MMP9, ARG1, galectin-9, TIM-3, VISTA and TGF-□ genes in HLA-DR myeloid cells, compared with HLA-DR antigen-presenting cells. *Epigenetics*, **2020**, 15, 1275-1288	5.7	10

88	Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. *Cancer Immunology, Immunotherapy*, **2020**, 69, 1989-1999	7.4	29
87	Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. *Frontiers in Immunology*, **2020**, 11, 1469	8.4	21
86	Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants. *Genes*, **2020**, 11,	4.2	7
85	Myeloid Cells in Circulation and Tumor Microenvironment of Colorectal Cancer Patients with Early and Advanced Disease Stages. *Journal of Immunology Research*, **2020**, 2020, 9678168	4.5	4
84	Transcriptomic Profiling of Tumor-Infiltrating CD4TIM-3 T Cells Reveals Their Suppressive, Exhausted, and Metastatic Characteristics in Colorectal Cancer Patients. *Vaccines*, **2020**, 8,	5.3	12
83	Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer. *Clinical Epigenetics*, **2020**, 12, 13	7.7	26
82	Differential expression of TIM-3 in circulation and tumor microenvironment of colorectal cancer patients. *Clinical Immunology*, **2020**, 215, 108429	9	4
81	Pembrolizumab Interferes with the Differentiation of Human FOXP3-Induced T Regulatory Cells, but Not with FOXP3 Stability, through Activation of mTOR. *Journal of Immunology*, **2020**, 204, 199-211	5.3	13
80	An evaluation of sorter induced cell stress (SICS) on peripheral blood mononuclear cells (PBMCs) after different sort conditions - Are your sorted cells getting SICS?. *Journal of Immunological Methods*, **2020**, 487, 112902	2.5	7
79	Epigenetic regulation of immune checkpoints and T cell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients. *Epigenomics*, **2020**, 12, 1871-1882	4.4	4
78	SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities. *Cancers*, **2020**, 12,	6.6	7
77	FoxP3 T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. *Cancer Letters*, **2020**, 490, 174-185	9.9	62
76	Differential gene expression of tumor-infiltrating CD4 T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis. *OncoImmunology*, **2020**, 9, 1825178	7.2	2
75	Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential. *Expert Opinion on Therapeutic Targets*, **2020**, 24, 1251-1262	6.4	7
74	Transcriptomic Analyses of Myeloid-Derived Suppressor Cell Subsets in the Circulation of Colorectal Cancer Patients. *Frontiers in Oncology*, **2020**, 10, 1530	5.3	3
73	Differential gene expression of tumor-infiltrating CD8 T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis **2020**, 8,		12
72	Immune checkpoints in the tumor microenvironment. *Seminars in Cancer Biology*, **2020**, 65, 1-12	12.7	62
71	Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. *Seminars in Cancer Biology*, **2020**, 65, 13-27	12.7	85

70	Investigation of the Effect of PD-L1 Blockade on Triple Negative Breast Cancer Cells Using Fourier Transform Infrared Spectroscopy. *Vaccines*, **2019**, 7,	5.3	6
69	Effect of pembrolizumab on CD4 CD25 , CD4 LAP and CD4 TIM-3 T cell subsets. *Clinical and Experimental Immunology*, **2019**, 196, 345-352	6.2	13
68	Treg-mediated acquired resistance to immune checkpoint inhibitors. *Cancer Letters*, **2019**, 457, 168-179	9.9	81
67	PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications. *Journal of Oncology*, **2019**, 2019, 3958908	4.5	27
66	PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer. *Cancers*, **2019**, 11,	6.6	33
65	Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGF and focal adhesion kinase (FAK) signaling. *Cell Death Discovery*, **2019**, 5, 109	6.9	38
64	Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4 T Cells. *Vaccines*, **2019**, 7,	5.3	30
63	Integrated Transcriptome and Pathway Analyses Revealed Multiple Activated Pathways in Breast Cancer. *Frontiers in Oncology*, **2019**, 9, 910	5.3	24
62	Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor-An Opportunity for Cancer Treatment. *Cells*, **2019**, 9,	7.9	11
61	Immune Checkpoints in Circulating and Tumor-Infiltrating CD4 T Cell Subsets in Colorectal Cancer Patients. *Frontiers in Immunology*, **2019**, 10, 2936	8.4	46
60	Transcriptomic Analyses Revealed Systemic Alterations in Gene Expression in Circulation and Tumor Microenvironment of Colorectal Cancer Patients. *Cancers*, **2019**, 11,	6.6	19
59	DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients. *OncoImmunology*, **2019**, 8, e1542918	7.2	28
58	Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer. *Immunology and Cell Biology*, **2018**, 96, 888-897	5	33
57	Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. *Expert Opinion on Therapeutic Targets*, **2018**, 22, 547-557	6.4	45
56	Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. *Immunology and Cell Biology*, **2018**, 96, 21-33	5	138
55	In-vitro effect of pembrolizumab on different T regulatory cell subsets. *Clinical and Experimental Immunology*, **2018**, 191, 189-197	6.2	31
54	DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. *Clinical Epigenetics*, **2018**, 10, 78	7.7	60
53	DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. *Clinical Epigenetics*, **2018**, 10, 104	7.7	40

52	Immune checkpoint inhibitors: recent progress and potential biomarkers. *Experimental and Molecular Medicine*, **2018**, 50, 1-11	12.8	814
51	Myeloid cells in circulation and tumor microenvironment of breast cancer patients. *Cancer Immunology, Immunotherapy*, **2017**, 66, 753-764	7.4	48
50	Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. *Oncotarget*, **2017**, 8, 33159-33171	3.3	73
49	Intratumoral FoxP3Helios Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. *Frontiers in Immunology*, **2017**, 8, 619	8.4	47
48	Comparison of Myeloid Cells in Circulation and in the Tumor Microenvironment of Patients with Colorectal and Breast Cancers. *Journal of Immunology Research*, **2017**, 2017, 7989020	4.5	6
47	Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients. *Oncotarget*, **2016**, 7, 14083-94	3.3	26
46	Combining FoxP3 and Helios with GARP/LAP markers to identify expanded Treg subsets in cancer patients.. *Journal of Clinical Oncology*, **2016**, 34, e23118-e23118	2.2	
45	Helios Should Not Be Cited as a Marker of Human Thymus-Derived Tregs. Commentary: Helios(+) and Helios(-) Cells Coexist within the Natural FOXP3(+) T Regulatory Cell Subset in Humans. *Frontiers in Immunology*, **2016**, 7, 276	8.4	30
44	Increased Levels of Circulating and Tumor-Infiltrating Granulocytic Myeloid Cells in Colorectal Cancer Patients. *Frontiers in Immunology*, **2016**, 7, 560	8.4	41
43	Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. *Vaccines*, **2016**, 4,	5.3	272
42	Downregulation of immunosuppressive environment in patients with chronic HBV hepatitis on maintained remission. *Frontiers in Immunology*, **2015**, 6, 52	8.4	2
41	Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S185-S198	12.7	738
40	Designing a broad-spectrum integrative approach for cancer prevention and treatment. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S276-S304	12.7	179
39	Myeloid-Derived Suppressor Cells **2015**, 1-8		6
38	Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP. *Oncotarget*, **2015**, 6, 20026-36	3.3	65
37	Novel expression of Neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases. *Expert Opinion on Therapeutic Targets*, **2015**, 19, 147-61	6.4	22
36	Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-versus IFN- *Oncotarget*, **2015**, 6, 4428-39	3.3	16
35	Neuropilin 1: function and therapeutic potential in cancer. *Cancer Immunology, Immunotherapy*, **2014**, 63, 81-99	7.4	138

34	Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. *Expert Opinion on Biological Therapy*, **2014**, 14, 931-45	5.4	24
33	Salmonella-mediated tumor regression involves targeting of tumor myeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity. *Cancer Immunology, Immunotherapy*, **2014**, 63, 587-99	7.4	43
32	In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells. *Expert Opinion on Pharmacotherapy*, **2014**, 15, 1489-99	4	6
31	Thymus-Derived, Peripherally Derived, and in vitro-Induced T Regulatory Cells. *Frontiers in Immunology*, **2014**, 5, 17	8.4	14
30	Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. *Journal of Immunology Research*, **2014**, 2014, 879897	4.5	96
29	Myeloid-derived suppressor cells in cancer: recent progress and prospects. *Immunology and Cell Biology*, **2013**, 91, 493-502	5	168
28	Comment on "Expression of Helios in peripherally induced Foxp3+ regulatory T cells". *Journal of Immunology*, **2012**, 189, 500; author reply 500-1	5.3	7
27	Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. *Clinical and Developmental Immunology*, **2012**, 2012, 708036		312
26	5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype. *Leukemia*, **2012**, 26, 1487-98	10.7	23
25	Macrophage inhibitory cytokine-1: a review of its pleiotropic actions in cancer. *Cancer Biomarkers*, **2012**, 11, 183-90	3.8	25
24	Circulating regulatory T cells in endometrial cancer: a role for age and menopausal status. *Immunological Investigations*, **2011**, 40, 62-75	2.9	9
23	Novel IFNELISPOT assay for detection of functional carcinoembryonic antigen-specific chimeric antigen receptor-redirected T cells. *Scandinavian Journal of Immunology*, **2011**, 74, 419-22	3.4	1
22	Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. *Clinical Immunology*, **2011**, 138, 85-96	9	58
21	Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. *Clinical Immunology*, **2011**, 140, 218-22	9	39
20	Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. *British Journal of Cancer*, **2010**, 102, 1129-36	8.7	184
19	Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. *Clinical Cancer Research*, **2010**, 16, 1662-72	12.9	200
18	T regulatory cells in cancer: recent advances and therapeutic potential. *Expert Opinion on Biological Therapy*, **2010**, 10, 1573-86	5.4	85
17	T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. *Clinical Cancer Research*, **2009**, 15, 6503-10	12.9	31

16	Frequency of human T regulatory cells in peripheral blood is significantly reduced by cryopreservation. *Journal of Immunological Methods*, **2009**, 347, 87-90	2.5	44
15	Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). *Cancer Immunology, Immunotherapy*, **2009**, 58, 1657-67	7.4	25
14	Novel therapeutic strategies by regulatory T cells in allergy. *Chemical Immunology and Allergy*, **2008** , 94, 150-157		3
13	Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. *Clinical Cancer Research*, **2008**, 14, 5292-9	12.9	77
12	Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. *Expert Opinion on Biological Therapy*, **2008**, 8, 385-95	5.4	17
11	An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. *Journal of Immunotherapy*, **2008**, 31, 820-9	5	39
10	Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. *Cancer Immunology, Immunotherapy*, **2008**, 57, 623-34	7.4	31
9	CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells. *Cancer Immunology, Immunotherapy*, **2008**, 57, 833-47	7.4	20
8	Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. *Cancer Immunology, Immunotherapy*, **2007**, 56, 1743-53	7.4	157
7	Immunology and immunotherapy approaches for prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2007**, 10, 224-36	6.2	10
6	Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer. *Clinical Immunology*, **2006**, 120, 91-8	9	12
5	Bead-isolated human CD4+CD25+ T regulatory cells are anergic and significantly suppress proliferation of CD4+CD25- T responder cells. *Clinical Immunology*, **2006**, 120, 232-3	9	4
4	CD8 T-cell recognition of human 5T4 oncofetal antigen. *International Journal of Cancer*, **2006**, 119, 1638-47	7.5	24
3	Role of regulatory T cells in allergy: implications for therapeutic strategy. *Inflammation and Allergy: Drug Targets*, **2006**, 5, 211-7		14
2	Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. *Immunology*, **2005**, 114, 204-12	7.8	118
1	Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. *International Immunology*, **2005**, 17, 1315-25	4.9	13